ライフサイエンスコーパス: cytoreductive

1 Interestingly, potent cytoreductive activity was demonstrated in a gastric car

2 ditional predictive factors were exposure to cytoreductive agents for leukemic transformation (OR = 3

3 ment of proliferative CMML usually relies on cytoreductive agents such as hydroxyurea, although ongoi

4 idly and expand their numbers in response to cytoreductive agents, such as cyclophosphamide (CY), and

5 cy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor model

6 f giving uniform dose-dense and dose-intense cytoreductive chemotherapy and integrating accelerated f

7 However, little is known about the impact of cytoreductive chemotherapy on HIV-1 reservoir dynamics,

8 topoietic stem cell transplantation combines cytoreductive chemotherapy with adoptive immunotherapy a

9 Despite cytoreductive chemotherapy, plasma uric acid concentrati

10 d returned to the patients without preceding cytoreductive chemotherapy.

11 epithelial cell integrity in the presence of cytoreductive chemotherapy.

12 f late B7 vaccines in combination with prior cytoreductive chemotherapy.

13 te minimal residual neoplastic disease after cytoreductive chemotherapy.

14 BMT) has been limited by toxicity related to cytoreductive conditioning and immune response.

15 ene therapy and underscore the importance of cytoreductive conditioning in this type of gene therapy

16 imerism and donor-specific tolerance without cytoreductive conditioning or immunosuppression.

17 cific hyporesponsiveness in the absence of a cytoreductive conditioning regimen.

18 or CAR-engineered HSCs would likely require cytoreductive conditioning to achieve long-term engraftm

19 etic stem cell transplantation without prior cytoreductive conditioning, although the mechanism of im

20 transplant SCID patients without the use of cytoreductive conditioning, but it is clear that this is

21 In the absence of irradiation or other cytoreductive conditioning, endogenous hematopoietic ste

22 f normal congenic bone marrow, without prior cytoreductive conditioning, which resulted in long-term

23 nction is severely compromised due to age or cytoreductive conditioning.

24 nsplanted donor HSCs, even in the absence of cytoreductive conditioning.

25 e status of > or = 60% who were eligible for cytoreductive craniotomy were enrolled.

26 Low-dose aspirin and cytoreductive drugs can be administered to this purpose,

27 Currently used cytoreductive drugs include hydroxyurea, mainly used in

28 gens, or immunomodulatory agents for anemia, cytoreductive drugs such as hydroxyurea for the splenome

29 Children with ST received more cytoreductive drugs than those with HT (P = .0006).

30 a s.c. A549 lung cancer xenograft model, the cytoreductive effect of Ad.TK(RC)(II) was enhanced when

31 In contrast, the cytoreductive efficacy of the replication-competent vect

32 y combining such forms of therapy with other cytoreductive measures including surgery.

33 ated genome-wide H3K36me3 profiles from four cytoreductive nephrectomies and SETD2 isogenic renal cel

34 The role of cytoreductive nephrectomy (CN) in metastatic renal cell

35 imilar to that of M-LR patients treated with cytoreductive nephrectomy and adjuvant IMT.

36 operative pazopanib therapy prior to planned cytoreductive nephrectomy and continued pazopanib therap

37 a method to select appropriate patients for cytoreductive nephrectomy are warranted.

38 patients who are most likely to benefit from cytoreductive nephrectomy but also allows access to trea

39 The timing of cytoreductive nephrectomy has also been controversial an

40 Cytoreductive nephrectomy has an established role in man

41 omy, and limited available evidence supports cytoreductive nephrectomy in appropriately selected pati

42 Importance: The role of cytoreductive nephrectomy in patients with metastatic re

43 ficacy of upfront pazopanib therapy prior to cytoreductive nephrectomy in previously untreated patien

44 The role of cytoreductive nephrectomy in the management of metastati

45 Additionally, cytoreductive nephrectomy is often indicated before the

46 ion, we propose that the observed effects of cytoreductive nephrectomy may be caused by resection of

47 Cytoreductive nephrectomy prior to systemic therapy sign

48 Cytoreductive nephrectomy should be considered to provid

49 argely been observed in the context of prior cytoreductive nephrectomy, and limited available evidenc

50 cessity, patient selection for and timing of cytoreductive nephrectomy.

51 In Cox regression analysis, response to cytoreductive or salvage therapy and B symptoms at relap

52 tion of remission, and favorable response to cytoreductive or salvage therapy were most predictive of

53 cer (HGSOC) and to evaluate CT indicators of cytoreductive outcome and survival in patients with BRCA

54 cal and CT features were not associated with cytoreductive outcome for patients with BRCA-mutant HGSO

55 CT indicators of cytoreductive outcome varied according to BRCA mutation

56 s between CT features, BRCA mutation status, cytoreductive outcome, and progression-free survival (PF

57 ly been demonstrated for the less completely cytoreductive pleurectomy procedure when combined with i

58 The cytoreductive potential of MV-Ed has been investigated i

59 targeted for gene transfer is facilitated by cytoreductive preconditioning such as high-dose total bo

60 These findings suggest that ultraradical cytoreductive procedures might be targeted for selected

61 The cytoreductive regimen consisted of hyperfractionated tot

62 erlying diagnoses, severe immune deficiency, cytoreductive regimen, and graft-versus-host reactions.

63 d appear to be key determinants of the early cytoreductive response to remission induction therapy an

64 e CA-125 level, surgical stage, ascites, and cytoreductive status.

65 The success of high-dose cytoreductive strategies depends not only on antitumor a

66 Survival based on the number of cytoreductive surgeries and the free interval between th

67 he roles of primary, interval, and secondary cytoreductive surgeries; second-look procedures; and pal

68 valuate outcome and long-term survival after cytoreductive surgery (CRS) and hyperthermic intraperito

69 cer may be treated with a curative intent by cytoreductive surgery (CRS) and hyperthermic intraperito

70 Cytoreductive surgery (CRS) and hyperthermic intraperito

71 zed trial demonstrated a survival benefit of cytoreductive surgery (CRS) and intraperitoneal chemothe

72 ould impact the failure-to-rescue rate after cytoreductive surgery (CRS) for peritoneal carcinomatosi

73 Cytoreductive surgery (CRS) with hyperthermic intraperit

74 perthermic intraperitoneal chemotherapy with cytoreductive surgery (HIPEC + CS).

75 sex (P < .001), age </= 65 years (P = .005), cytoreductive surgery (P < .001), and epithelioid histol

76 ostic laparoscopy can prevent futile primary cytoreductive surgery (PCS) by identifying patients with

77 mains about the relative benefits of primary cytoreductive surgery (PCS) vs neoadjuvant chemotherapy

78 nt chemotherapy (NACT) compared with primary cytoreductive surgery (PCS).

79 fied by a general paradigm of maximally safe cytoreductive surgery and advanced radiation delivery te

80 inical remission after completion of primary cytoreductive surgery and chemotherapy at 6 National Can

81 e demonstrates the feasibility and safety of cytoreductive surgery and HIPEC via the laparoscopic rou

82 A large proportion of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal c

83 Patients with PM from CRC admitted for cytoreductive surgery and hyperthermic intraperitoneal c

84 Cytoreductive surgery and hyperthermic intraperitoneal c

85 Therefore, investigators have applied cytoreductive surgery and hyperthermic perioperative che

86 impact on progression-free survival (PFS) of cytoreductive surgery and international variations in su

87 All patients with colorectal PC referred for cytoreductive surgery and intraperitoneal chemotherapy (

88 ere managed by a treatment regimen that used cytoreductive surgery and intraperitoneal chemotherapy.

89 with PC and synchronous LM who had undergone cytoreductive surgery and LM resection followed by intra

90 with routine observation (OBS) after primary cytoreductive surgery and platinum-based chemotherapy in

91 The therapeutic value of cytoreductive surgery and radiation therapy for posterio

92 l carcinomatosis (PC) who underwent complete cytoreductive surgery and resection of LM, followed by i

93 atients with advanced-stage disease, maximum cytoreductive surgery appears to be beneficial.

94 The survival benefits of cytoreductive surgery are also applicable to women with

95 years) with abdominopelvic CT before primary cytoreductive surgery available through the Cancer Imagi

96 arian cancer who underwent CT before primary cytoreductive surgery between 1997 and 2004 (mean age, 6

97 PURPOSE OF REVIEW: Cytoreductive surgery combined with hyperthermic intrape

98 The efficacy of cytoreductive surgery combined with perioperative intrap

99 The current evidence suggests that cytoreductive surgery combined with perioperative intrap

100 he expansion of treatment options, including cytoreductive surgery followed by chemotherapy with hype

101 gical malignancy that is commonly treated by cytoreductive surgery followed by cisplatin treatment.

102 e was randomly assigned to undergo secondary cytoreductive surgery followed by three more cycles of c

103 fic immunotherapy should be considered after cytoreductive surgery for advanced melanoma.

104 Interval cytoreductive surgery has been shown to confer a surviva

105 mic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery have been shown to benefit selecte

106 e availability of retroperitoneal staging or cytoreductive surgery if necessary.

107 ospective study of CT images obtained before cytoreductive surgery in 46 women with HGSOC, whose tumo

108 A new treatment strategy starts with cytoreductive surgery in an attempt to remove all visibl

109 Despite continuing debates around cytoreductive surgery in malignant gliomas, there is bro

110 troy small residual mucinous tumour nodules, cytoreductive surgery is combined with intraperitoneal c

111 However, primary cytoreductive surgery is preferred if there is a high li

112 As such, extensive cytoreductive surgery is required prior to IPC.

113 in metastatic melanoma tumors obtained from cytoreductive surgery of AJCC stage IV melanoma patients

114 r; however, a subset of patients who undergo cytoreductive surgery of distant metastases survive for

115 rent disease may be eligible for a secondary cytoreductive surgery or may require a surgical interven

116 ecurrence develops are candidates for repeat cytoreductive surgery plus intraperitoneal chemotherapy

117 The impact on survival of secondary cytoreductive surgery requires more investigation.

118 We evaluated the effect of adding secondary cytoreductive surgery to postoperative chemotherapy on p

119 red to be maximal, the addition of secondary cytoreductive surgery to postoperative chemotherapy with

120 Primary cytoreductive surgery was associated with improved survi

121 h advanced ovarian carcinoma in whom primary cytoreductive surgery was considered to be maximal, the

122 Histology, grade, stage, and success of cytoreductive surgery were similar for hereditary and sp

123 apy alone has recently been demonstrated for cytoreductive surgery when combined with intraoperative

124 Cytoreductive surgery with hyperthermic intraperitoneal

125 Women who are fit for primary cytoreductive surgery, and with potentially resectable d

126 e either neoadjuvant chemotherapy or primary cytoreductive surgery.

127 18)F-FES PET/CT was performed shortly before cytoreductive surgery.

128 and hemodynamic findings when injected after cytoreductive surgery.

129 e a week either during tumor growth or after cytoreductive surgery.

130 apy regimens with or without prior secondary cytoreductive surgery.

131 n with carboplatin and taxane regimens after cytoreductive surgery.

132 The cytoreductive surgical procedures were sampled, and dise

133 With increasing radicality of cytoreductive surgical techniques and sophistication of

134 lliation (by excision and a variety of other cytoreductive techniques), they each are treated with an

135 ariable, there is greater potential need for cytoreductive therapies (eg, interferon-alpha, cladribin

136 antimediator therapies and consideration of cytoreductive therapies for those with treatment-refract

137 Cytoreductive therapy aims to normalize platelet counts

138 cilitates hematopoietic reconstitution after cytoreductive therapy by: (1) delaying the exhaustion of

139 irst recurrence after chemotherapy, received cytoreductive therapy followed by high-dose etoposide, c

140 Prompt reconstitution of hematopoiesis after cytoreductive therapy is essential for patient recovery

141 Cytoreductive therapy prior to HSCT is advised for patie

142 Patients responding to cytoreductive therapy showed a significant decrease in K

143 samples from patients that had not undergone cytoreductive therapy were specifically chosen for COX i

144 erive additional antithrombotic benefit from cytoreductive therapy with hydroxyurea as first-line and

145 lusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocy

146 In animals administered cytoreductive therapy, the use of TPO is associated with

147 r enhanced as in first-line therapy or after cytoreductive therapy.

148 oduced into tumor cells by viral vectors for cytoreductive therapy.

149 Most patients with ovarian cancer undergo cytoreductive therapy.

150 ous regimen-related toxicity after high-dose cytoreductive therapy.

151 One patient was excluded due to concomitant cytoreductive therapy.

152 The latter might benefit from cytoreductive treatment before HCT.

153 gs can be administered to this purpose, with cytoreductive treatment being primarily given to patient

154 immunocompetent adults) has always required cytoreductive treatment of recipients with irradiation o

155 anagrelide, approved immunomodulators, or no cytoreductive treatment).

156 hase III trial determining whether intensive cytoreductive treatment, followed by interferon consolid

157 nosine [2-CdA]) is a synthetic purine analog cytoreductive treatment, for which efficacy is mostly re